Cargando…
Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly impor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505927/ https://www.ncbi.nlm.nih.gov/pubmed/37727211 http://dx.doi.org/10.3389/fonc.2023.1179595 |
_version_ | 1785107011186196480 |
---|---|
author | Yan, Li Zhang, Zhengchao Wang, Ting Yuan, Leihong Sun, Xiaoke Su, Pengxiao |
author_facet | Yan, Li Zhang, Zhengchao Wang, Ting Yuan, Leihong Sun, Xiaoke Su, Pengxiao |
author_sort | Yan, Li |
collection | PubMed |
description | Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly important for clinical management of patients. Conventional imaging examinations such as MRI and CT cannot accurately diagnose the pathological stages of advanced PCa, especially metastatic lymph node (LN) stages. As a result, developing an accurate molecular targeted diagnosis is crucial for advanced PCa. Prostate specific membrane antigen (PSMA) is of great value in the diagnosis of PCa because of its specific expression in PCa. At present, researchers have developed positron emission tomography (PET) targeting PSMA. A large number of studies have confirmed that it not only has a higher tumor detection rate, but also has a higher diagnostic efficacy in the pathological stage of advanced PCa compared with traditional imaging methods. This review summarizes recent studies on PSMA targeted PET in PCa diagnosis, analyzes its value in PCa diagnosis in detail, and provides new ideas for urological clinicians in PCa diagnosis and clinical management. |
format | Online Article Text |
id | pubmed-10505927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105059272023-09-19 Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review Yan, Li Zhang, Zhengchao Wang, Ting Yuan, Leihong Sun, Xiaoke Su, Pengxiao Front Oncol Oncology Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly important for clinical management of patients. Conventional imaging examinations such as MRI and CT cannot accurately diagnose the pathological stages of advanced PCa, especially metastatic lymph node (LN) stages. As a result, developing an accurate molecular targeted diagnosis is crucial for advanced PCa. Prostate specific membrane antigen (PSMA) is of great value in the diagnosis of PCa because of its specific expression in PCa. At present, researchers have developed positron emission tomography (PET) targeting PSMA. A large number of studies have confirmed that it not only has a higher tumor detection rate, but also has a higher diagnostic efficacy in the pathological stage of advanced PCa compared with traditional imaging methods. This review summarizes recent studies on PSMA targeted PET in PCa diagnosis, analyzes its value in PCa diagnosis in detail, and provides new ideas for urological clinicians in PCa diagnosis and clinical management. Frontiers Media S.A. 2023-09-01 /pmc/articles/PMC10505927/ /pubmed/37727211 http://dx.doi.org/10.3389/fonc.2023.1179595 Text en Copyright © 2023 Yan, Zhang, Wang, Yuan, Sun and Su https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yan, Li Zhang, Zhengchao Wang, Ting Yuan, Leihong Sun, Xiaoke Su, Pengxiao Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title | Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title_full | Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title_fullStr | Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title_full_unstemmed | Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title_short | Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review |
title_sort | application of targeted diagnosis of psma in the modality shift of prostate cancer diagnosis: a review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505927/ https://www.ncbi.nlm.nih.gov/pubmed/37727211 http://dx.doi.org/10.3389/fonc.2023.1179595 |
work_keys_str_mv | AT yanli applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview AT zhangzhengchao applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview AT wangting applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview AT yuanleihong applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview AT sunxiaoke applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview AT supengxiao applicationoftargeteddiagnosisofpsmainthemodalityshiftofprostatecancerdiagnosisareview |